Q1 2025 Medicover AB Earnings Call Transcript
Key Points
- Medicover AB (MCVEF) reported strong top-line growth with organic growth exceeding 14%.
- The company achieved significant margin expansion, with EBITDA margin up 1.6 percentage points and EBIT margin up 2.4 percentage points.
- Poland continues to be a strong market for healthcare services, contributing 52% of revenue with 22% growth.
- Diagnostics segment showed robust performance with double-digit organic growth and margin expansion, particularly in Germany's private pay revenue.
- The company achieved its year-end 2025 financial targets ahead of schedule, with organic revenue trading around €2.3 billion and adjusted EBITDA above $350 million.
- India experienced a particularly weak quarter, with revenue growth flat at 1% and challenges in medical tourism due to visa issues.
- The company faced losses from six immature hospitals, five of which are in India, contributing to a $3.9 million EBITDA loss.
- The public reimbursement segment in Germany offers no price compensation, limiting growth potential in that area.
- The Polish hospital business was slightly behind plans for the quarter, indicating variability in performance.
- The company anticipates a temporary increase in leverage above the target of 3.5 times due to recent acquisitions.
Good morning everyone and welcome to the 1st quarter, 2025 results presentation.
In fact, I think it is robably the best report we have presented, possibly with the exception of one or two COVID, the doped pandemic reports, but in terms of the broad business, it is definitely the best report we have published since we listed the company now.
8 years ago. It's a combination of factors, we see continued strong top line growth.
Organic growth was more than 14%.
Most importantly, the further down, the profit and loss statement, you see, the more op operational leverage you see coming down in margins expanding.
I beta margin up 1.6% points. EBIT margin up 2.4% points, and you know it goes on as you flow through down the profit and loss statement, which is exactly what we have been focused on, it is exactly what we have been reporting to you over the past 4 or 5 quarters. It is just that it, as the numbers get bigger, it becomes a bit more pronounced, and that is really what we, what we see here.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
